# Sacituzumab tirumotecan endometrial cancer research

> Developing situation record from CLSTR: https://clstr.news/situations/sacituzumab-tirumotecan-endometrial-cancer-research
> Updated: 2026-11-10T07:27:31.000Z. Sources: 7. Developments: 2.

Clinical trial results for the experimental antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) indicate significant improvements for patients with advanced or recurrent endometrial cancer. Data from the Phase 3 TroFuse-005 international trial, involving 776 women, showed that sac-TMT reduced the risk of death by 32% and the risk of disease progression or death by 41% compared to standard chemotherapy.

Key metrics from the study include a median overall survival of 19 months for the sac-TMT group versus 12 months for the control group, and an objective response rate of 35.1% compared to 17.3% in the chemotherapy group. The drug functions by targeting the Trop2 protein to deliver chemotherapy directly to tumor cells. Reported side effects include oral mucositis and low blood counts.

## Timeline

### 2026-11-10: Scientific research explores brain health, nutrition, and cognitive function

New research examines the impact of Omega-3 supplements on memory, the metabolic causes of mental fatigue, the role of Vitamin B12 in brain health, and the therapeutic potential of psilocybin.

7 sources. https://clstr.news/cluster/medical-research-highlights-new-developments-in-cancer-treatment-and-mental-health

### 2026-10-26: Sacituzumab tirumotecan shows promise in treating advanced endometrial cancer

A Phase 3 trial of sacituzumab tirumotecan (sac-TMT) shows a 32% reduction in death risk for patients with advanced or recurrent endometrial cancer compared to standard chemotherapy.

17 sources. https://clstr.news/cluster/endometrial-health-research-shows-progress-in-regeneration-and-cancer-treatment

---
Cite as: Sacituzumab tirumotecan endometrial cancer research. CLSTR, https://clstr.news/situations/sacituzumab-tirumotecan-endometrial-cancer-research
